Simplify Asset Management Inc. Sells 1,343,513 Shares of Athira Pharma, Inc. $ATHA

Simplify Asset Management Inc. decreased its stake in shares of Athira Pharma, Inc. (NASDAQ:ATHA) by 90.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 149,279 shares of the company’s stock after selling 1,343,513 shares during the period. Simplify Asset Management Inc. owned about 3.79% of Athira Pharma worth $618,000 at the end of the most recent quarter.

Separately, BML Capital Management LLC raised its holdings in shares of Athira Pharma by 0.9% in the second quarter. BML Capital Management LLC now owns 3,230,667 shares of the company’s stock valued at $976,000 after purchasing an additional 30,000 shares during the last quarter. 57.12% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Mizuho set a $4.00 price target on shares of Athira Pharma in a report on Friday, September 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Athira Pharma in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell” and a consensus target price of $4.00.

Athira Pharma Stock Up 0.3%

Athira Pharma stock opened at $7.50 on Tuesday. The firm has a 50 day moving average price of $4.72 and a 200-day moving average price of $4.12. Athira Pharma, Inc. has a twelve month low of $2.20 and a twelve month high of $8.36. The company has a market capitalization of $29.55 million, a P/E ratio of -0.77 and a beta of 2.95.

Athira Pharma (NASDAQ:ATHA) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($1.68) EPS for the quarter, missing the consensus estimate of ($0.17) by ($1.51). Equities analysts expect that Athira Pharma, Inc. will post -2.35 EPS for the current fiscal year.

Athira Pharma Profile

Athira Pharma, Inc is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).

The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system.